期刊文献+

60岁以下成人Ph阴性急性淋巴细胞白血病患者自体造血干细胞移植疗效分析——单中心BDHALL2000/02方案临床研究结果 被引量:1

Autologous hematopoietic stem cell transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: a single center experience from the BDHALL2000/02 protocol
原文传递
导出
摘要 目的 探讨自体造血干细胞移植(AHSCT)治疗年轻成人Ph-急性淋巴细胞白血病(ALL)的疗效.方法 纳入56例于2000年1月至2007年12月接受BDHALL2000/02方案治疗并于CR1期行AHSCT的成人(15~60岁)Ph ALL患者,对其进行生存和预后影响因素分析.结果 56例患者中标危、中危和高危者分别为23例(41.1%)、19例(33.9%)和14例(25.0%).中位随访75(7~177)个月.5年总生存(0S)、无事件生存(EFS)、无复发生存(RFS)、复发率分别为(51.8±6.7)%、(51.8±6.7)%、(60.5±6.9)%、(39.1±6.9)%.标、中、高危组患者的5年OS率分别为(60.9±10.2)%、(52.6±11.5)%和(35.7±12.8)%,EFS率分别为(60.9± 10.2)%、(52.6±11.5)%和(35.7±12.8)%,RFS率分别为(68.3±9.9)%、(62.5± 12.1)%和(44.9± 14.1)%,复发率分别为(31.7±9.9)%、(37.5±12.1)%和(55.1±14.1)%.标危和中危组、中危和高危组患者的上述指标比较差异均无统计学意义(P值均>0.05);标危组患者的OS、EFS率高于高危组(P值分别为0.040和0.029),而RFS和复发率差异则无统计学意义(P值均>0.05).对年龄≥35岁、完全缓解时间超过5周、初诊白细胞水平、免疫表型(B/T)、伴髓系表达、超二倍体染色体核型、复杂核型、完全缓解至AHSCT间隔时间、预处理方案是否包含TBI等进行单因素分析,均未显示对预后存在影响(P值均>0.05).结论 年轻成人Ph-ALL患者经BDHALL2000/02方案治疗可以获得较高的缓解率,缓解后给予早期序贯强化/巩固治疗后进行AHSCT疗效显著,是标危、中危组及无合适供者的高危组患者的合适选择. Objective To evaluate the results of autologous hematopoietic stem cell transplantation (auto-HSCT) in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph-ALL).Methods From January 2000 to December 2007,the clinical data of auto-HSCT in adults Ph ALL with complete remession (CR) 1 according to BDHALL2000/02 protocol were analyzed.Results A total of 56 patients were enrolled and the probabilities of standard risk,intermediated risk and high-risk group were 41.1%,33.9%,and 25.0%,respectively.After a median follow-up of 75 months (range 7-177 months),the 5-year overall survival (OS),events free survival (EFS) and relapse free survival (RFS) were (51.8 ± 6.7)%,(51.8 ± 6.7)%,and (60.5 ± 6.9)%,respectively.And the 5-year accumulative relapse rate was (39.1±6.9)%.The 5-year OS of standard risk,intermediate risk,high-risk group were (60.9±10.2)%,(52.6±11.5)%,and (35.7±12.8)%,respectively.The 5-year RFS among three groups were (68.3±9.9)%,(62.5±12.1)%,and (44.9±14.1)%,respectively.The 5-year EFS among three groups were (60.9±10.2)%,(52.6± 11.5)%,and (35.7±12.8)%,respectively.The 5-year accumulative relapse rate among three groups were (31.7±9.9) %,(37.5 ±12.1) %,and (55.1±14.1) %,respectively.There was no statistical significance of any survival rates between standard and intermediate risk groups,just as intermediate and high-risk groups.The OS and EFS in standard risk group were superior to those in highrisk group (P=0.040 and P=0.029,respectively),while there was no statistical significance of RFS and accumulative relapse rate between the two groups.The clinical factors listed below did not influenced the prognosis in the univariate analysis (P>0.05),including more than 5 weeks reaching to CR,WBC count at diagnosis,different immunophenotype (T or B cells),myeloid antigen expression,hyperdiploid chromosome karyotype,complex chromosome abnormality,conditioning regimen with or without TBI,duration between transplantation and diagnosis.Conclusions Ph-ALL adults could achieve a satisfactory CR and better survial according to BDHALL2000/02 protocol followed by auto-HSCT,especially for the standard or intermediate risk group,and no-donors high-risk patients.
出处 《中华血液学杂志》 CAS CSCD 北大核心 2015年第6期480-484,共5页 Chinese Journal of Hematology
基金 十二五国家科技支撑计划项目(2014BAI0912)
关键词 造血干细胞移植 白血病 淋巴样 费城染色体 成年人 Hematopoietic stem cell transplantation Leukemia, lymphoid Philadelphia chromosome Adult
  • 引文网络
  • 相关文献

参考文献11

  • 1Yanada M, Matsuo K, Suzuki T, et al. Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: a meta analysis[J]. Cancer, 2006, 106(12):2657-2663.
  • 2Ram R, Gafter-Gvili A, Vidal L, et al. Management of adult patients with acute lymphoblastic leukemia in first complete remission: systematic review and meta-analysis[J]. Cancer, 2010, 116(14): 3447-3457.
  • 3邹德慧,韩明哲,冯四洲,李成文,邱录贵,姜容,韩俊领,王玫,张莉,韩忠朝,严文伟.自体造血干细胞移植治疗急性淋巴细胞白血病30例疗效分析[J].中华血液学杂志,2000,21(2):74-76. 被引量:9
  • 4G?kbuget N, Hoelzer D, Arnold R, et al. Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL)[J]. Hematol Oncol Clin North Am, 2000, 14(6):1307-1325.
  • 5Ribera JM, Oriol A, Bethencourt C, et al. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial[J]. Haematologica, 2005, 90(10):1346-1356.
  • 6Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)[J]. Blood, 2008, 111(4):1827-1833.
  • 7Granados E, de La Cámara R, Madero L, et al. Hematopoietic cell transplantation in acute lymphoblastic leukemia: better long term event-free survival with conditioning regimens containing total body irradiation[J]. Haematologica, 2000, 85(10): 1060-1067.
  • 8Kiehl MG, Kraut L, Schwerdtfeger R, et al. Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission[J]. J Clin Oncol, 2004, 22(14): 2816-2825.
  • 9Shi-Xia X, Xian-Hua T, Hai-Qin X, et al. Total body irradiation plus cyclophosphamide versus busulphan with cyclophosphamide as conditioning regimen for patients with leukemia undergoing allogeneic stem cell transplantation: a meta-analysis[J]. Leuk Lymphoma, 2010, 51(1): 50-60.
  • 10Sirohi B, Powles R, Treleaven J, et al. The role of maintenance chemotherapy after autotransplantation for acute lymphoblastic leukemia in first remission: single-center experience of 100 patients[J]. Bone Marrow Transplant, 2008, 42(2):105-112.

二级参考文献1

共引文献8

同被引文献11

引证文献1

二级引证文献3

;
使用帮助 返回顶部